<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03048578</url>
  </required_header>
  <id_info>
    <org_study_id>16-01527</org_study_id>
    <nct_id>NCT03048578</nct_id>
  </id_info>
  <brief_title>Clinical Efficacy and Safety of Using 3.0mg Liraglutide to Treat Weight Regain After Roux-en-Y Gastric Bypass Surgery</brief_title>
  <official_title>Clinical Efficacy and Safety of Using 3.0mg Liraglutide to Treat Weight Regain After Roux-en-Y Gastric Bypass Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blinded, placebo-controlled trial of liraglutide versus placebo&#xD;
      over a follow-up period of 12 months in patients at least 18 months following Roux-en-Y&#xD;
      gastric bypass (RYGB) who are experiencing weight regain. This study will assess the efficacy&#xD;
      of liraglutide in improving cardiometabolic risk profile (as indicated by serum lipids,&#xD;
      HbA1c, and waist circumference) and quality of life (as assessed by PHQ-9 (Patient Health&#xD;
      Questionnaire), versus placebo in patients at least 18 months following RYGB who are&#xD;
      experiencing weight regain as well as the safety of liraglutide in this patient population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The specific aims of this study are to:&#xD;
&#xD;
        -  To evaluate the effects of liraglutide on body weight loss in patients who are&#xD;
           experiencing weight regain following RYGB.&#xD;
&#xD;
        -  To evaluate the effects of liraglutide on cardiometabolic risk and quality of life in&#xD;
           patients who are experiencing weight regain following RYGB.&#xD;
&#xD;
        -  To evaluate the safety of liraglutide in post-RYGB subjects.&#xD;
&#xD;
        -  To evaluate the changes in obesity-related comorbid conditions in patients who are&#xD;
           experiencing weight regain following RYGB.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 22, 2017</start_date>
  <completion_date type="Actual">March 2, 2021</completion_date>
  <primary_completion_date type="Actual">March 2, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomization will be 2:1 (drug:placebo) with stratification by gender and percent post-operative TBWL (25%, 25 - 49.9%).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects losing at least 5% enrollment body weight measured using Cochran-Mantel-Haenszel test</measure>
    <time_frame>12 Months</time_frame>
    <description>Test used in the analysis of stratified or matched categorical data. It allows testing of the association between a binary predictor or treatment and a binary outcome such as case or control status while taking into account the stratification</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">132</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Saxenda</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Week 1: 0.6mg/day Week 2: 1.2mg/day Week 3: 1.8mg/day Week 4: 2.4mg/day Week 5 and Onward: 3.0mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Week 1: 0.6mg/day Week 2: 1.2mg/day Week 3: 1.8mg/day Week 4: 2.4mg/day Week 5 and Onward: 3.0mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saxenda</intervention_name>
    <description>Week 1: 0.6mg/day Week 2: 1.2mg/day Week 3: 1.8mg/day Week 4: 2.4mg/day Week 5 and Onward: 3.0mg/day</description>
    <arm_group_label>Saxenda</arm_group_label>
    <other_name>Victoza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneous Saline Solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥18 months status-post RYGB&#xD;
&#xD;
          -  BMI 27 kg/m2 or greater in the presence of at least one weight-related comorbid&#xD;
             condition&#xD;
&#xD;
          -  BMI 30 kg/m2 or greater&#xD;
&#xD;
          -  Regain of ≥10% of maximum TBWL post-RYGB&#xD;
&#xD;
          -  Ability to provide informed consent before any trial-related activities&#xD;
&#xD;
          -  Express willingness to follow protocol requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy at time of enrollment&#xD;
&#xD;
          -  Intention of becoming pregnant or breast feeding in the next 12 months&#xD;
&#xD;
          -  Females of childbearing potential who are not using adequate contraceptive methods&#xD;
&#xD;
          -  Presence of acute psychiatric problems or immaturity which would compromise&#xD;
             cooperation with the study protocol&#xD;
&#xD;
          -  Presence of biliary disease&#xD;
&#xD;
          -  Known or suspected allergy to liraglutide or any product components&#xD;
&#xD;
          -  Personal or family history of medullary thyroid carcinoma or multiple endocrine&#xD;
             neoplasia syndrome type 2&#xD;
&#xD;
          -  History of pancreatitis&#xD;
&#xD;
          -  History of alcoholism&#xD;
&#xD;
          -  History of Type 1 DM (Diabetes Mellitus)&#xD;
&#xD;
          -  History of previous bariatric surgery other than RYGB except h/o LAGB and band&#xD;
             removal.&#xD;
&#xD;
          -  &gt;10 years status-post RYGB&#xD;
&#xD;
          -  &lt; 25% TBWL at post-RYGB weight nadir&#xD;
&#xD;
          -  &gt;50% post-operative TBWL at time of screening&#xD;
&#xD;
          -  Simultaneous use of any weight loss medications&#xD;
&#xD;
          -  Use of insulin at the time of enrollment&#xD;
&#xD;
          -  Current use of any GLP-1 agonist medication&#xD;
&#xD;
          -  History of taking any GLP-1 agonist medication&#xD;
&#xD;
          -  Participation in another ongoing clinical study&#xD;
&#xD;
          -  Conditions that, in the opinion of the principal investigator, may jeopardize the&#xD;
             patient's well-being and/or the soundness of this clinical study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Holly Lofton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 7, 2017</study_first_submitted>
  <study_first_submitted_qc>February 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2017</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Roux-en-Y gastric bypass (RYGB)</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

